ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Holdings (Nasdaq: ALXO) announced that its Compensation Committee granted an inducement stock option to purchase 600,000 shares of common stock to new Chief Financial Officer Harish Shantharam, effective January 21, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ALX Oncology Holdings (Nasdaq: ALXO) announced that its Compensation Committee granted an inducement stock option to purchase 600,000 shares of common stock to new Chief Financial Officer Harish Shantharam, effective January 21, 2025. The stock option, granted under the company's 2025 Inducement Equity Incentive Plan, has an exercise price of $1.65 per share, matching the closing price on the grant date.
The vesting schedule includes 25% of shares vesting after one year from the grant date, with the remaining shares vesting monthly at one forty-eighth of the total over the following three years, contingent on continued employment. The grant was made as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- Successful recruitment of new Chief Financial Officer
- Stock options align executive interests with shareholders
Negative
- Potential future dilution from 600,000 shares of stock options
- Low stock price of $1.65 indicates challenging market conditions
Details
News Market Reaction – ALXO
The recorded move for ALXO in the trading session of this news was -9.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology’s common stock to Harish Shantharam, the Company’s Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam’s inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock option has an exercise price of
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Company Contact:
Allison Dillon, Chief Business Officer, ALX Oncology
ir@alxoncology.com
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.